The allegations relate to a clinical trial — known as HIVNET 012 and funded by the US National Institutes of Health (NIH) — which began in 1997 in Uganda.In 1999 and in 2003, the scientists running the trial reported that nevirapine drastically cut mother-to-child transmission of HIVThe Associated Press stories drew on internal communications between Edmund Tramont, head of the NIH's Division of AIDS, and his subordinates, who were concerned about standards of record keeping in the trial.The drug, nevirapine, is used to help prevent mother-to-baby transmission of HIV.But stories published by the Associated Press earlier this month re-ignited controversy in Africa over whether nevirapine is safe and effective, raising fears that many women there will stop taking the drug.
If this level of treatment scale up continues, it is estimated that the world will meet its global target of 30 million people on treatment by 2020.14 We met the 2015 target of 15 million people on treatment and we are on track to double that number to 30 million and meet the 2020 target.
“Ed Tramont is a man of integrity and common sense, and he has probably done more than anybody at the NIH to improve the infrastructure for conducting these trials in developing countries,” says Brooks Jackson, a pathologist at Johns Hopkins Medicine in Baltimore, who led HIVNET 012.
Brooks Jackson adds that he stands by the trial's results: “There's no question in my mind that single-dose nevirapine is safe and efficacious, and now that's been supported by several other studies independent of ours.”Even activists who often clash with the NIAID say that top scientists there correctly interpreted evidence from the trial, despite some flaws in the study.
It's not easy to find that "someone special." Add HIV to the equation, and it's even more complicated.
So what's the most practical, effective way to meet someone these days? Wait to bump into that perfect person in the produce aisle of the local grocery store, and you'll be waiting forever.